Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases.
adalimumab
inflammatory bowel disease
infliximab
sex differences
spondyloarthritis
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
09
2018
accepted:
15
01
2019
entrez:
13
2
2019
pubmed:
13
2
2019
medline:
13
2
2019
Statut:
epublish
Résumé
Spondyloarthritis (SpA) and inflammatory bowel diseases (IBD) are chronic inflammatory diseases characterized by an aberrant immune response and inflammation with a key role for TNF in their pathogenesis. Accordingly, TNF-inhibiting therapy (TNFi) has dramatically improved the management of these diseases. However, about 30% of patients discontinue TNFi for lack of response, loss of response, and side effects and/or adverse events. Thus, the possibility to identify in advance those patients who will have a good response to TNFi would be extremely beneficial. The aim of this study was to investigate differences between males and females with either SpA or IBD in response to TNFi molecules, i.e., infliximab (IFX) and adalimumab (ADA), considering the reasons for TNFi withdraw. Data of 594 patients, 349 with IBD (M/F: 194/155) and 245 with SpA (M/F: 123/122), previously unexposed to TNFi, were collected. In the IBD group, the rate of female patients discontinuing ADA was significantly higher than that of male patients (
Identifiants
pubmed: 30745872
doi: 10.3389/fphar.2019.00047
pmc: PMC6360251
doi:
Types de publication
Journal Article
Langues
eng
Pagination
47Références
Immunopharmacol Immunotoxicol. 1992;14(3):451-61
pubmed: 1517530
Gastroenterol Hepatol. 2008 Aug-Sep;31(7):421-6
pubmed: 18783686
Gut. 1991 Aug;32(8):913-7
pubmed: 1885073
Inflamm Bowel Dis. 2009 Mar;15(3):328-34
pubmed: 18942752
Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1609-14
pubmed: 19102352
World J Gastroenterol. 2012 Dec 21;18(47):6967-73
pubmed: 23322995
Clin Chem Lab Med. 2013 Apr;51(4):713-27
pubmed: 23515103
Clin Dev Immunol. 2013;2013:369202
pubmed: 23840241
Mediators Inflamm. 2014;2014:325129
pubmed: 25045210
Ann Rheum Dis. 2016 Mar;75(3):499-510
pubmed: 26644232
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
J Crohns Colitis. 2017 Jan;11(1):3-25
pubmed: 27660341
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
Ann Rheum Dis. 2017 Jun;76(6):978-991
pubmed: 28087505
J Crohns Colitis. 2017 Jun 1;11(6):649-670
pubmed: 28158501
Inflamm Bowel Dis. 2017 Jun;23(6):976-985
pubmed: 28333755
Int J Mol Sci. 2017 Sep 14;18(9):null
pubmed: 28906475
J Gastroenterol Hepatol. 2018 May;33(5):1031-1038
pubmed: 29087616
Nat Rev Rheumatol. 2017 Nov 21;13(12):707-718
pubmed: 29158574
Ther Adv Chronic Dis. 2018 Mar;9(3):77-87
pubmed: 29511503
Int J Rheum Dis. 2018 Apr;21(4):836-842
pubmed: 29611349
Curr Rheumatol Rep. 2018 May 12;20(6):35
pubmed: 29754330
Ther Adv Musculoskelet Dis. 2018 Jun;10(5-6):129-139
pubmed: 29942364
Gastroenterology. 2018 Oct;155(4):1079-1089.e3
pubmed: 29958857
Gut. 1993 Dec;34(12):1705-9
pubmed: 8031350
Dig Dis Sci. 1997 Jul;42(7):1557-66
pubmed: 9246063